Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
43 hedge funds and large institutions have $9.79M invested in Accelerate Diagnostics in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 11 reducing their positions, and 1 closing their positions.
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
13% more funds holding
Funds holding: 38 → 43 (+5)
9% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 11
33% less capital invested
Capital invested by funds: $14.7M → $9.79M (-$4.91M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $2K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GAM
Griffin Asset Management
New York
|
+$186K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$148K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$81.7K |
| 4 |
Millennium Management
New York
|
+$73.8K |
| 5 |
SIMG
Sonora Investment Management Group
Tucson,
Arizona
|
+$37.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$712K |
| 2 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$132K |
| 3 |
AF
Allworth Financial
Folsom,
California
|
-$79.3K |
| 4 |
CIA
Cladis Investment Advisory
Billings,
Montana
|
-$23.5K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$21K |
AXDX Hedge Fund Activity: Q4 2023 in Review
43 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q4 2023, worth a combined $9.79M — down 33% from $14.7M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new AXDX positions and 1 closed out — a net gain of 5 holders — while 10 added to existing stakes and 11 trimmed.
The largest buyer was Griffin Asset Management, adding an estimated $186K. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $712K sold.
- 43 institutional investors held Accelerate Diagnostics (AXDX) as of Q4 2023, up from 38 in Q3 2023.
- Funds reported $9.79M of Accelerate Diagnostics stock for Q4 2023, down 33% quarter-over-quarter.
- 6 funds opened new Accelerate Diagnostics positions in Q4 2023 and 1 closed out, a net change of +5 holders.
- The largest Accelerate Diagnostics buyer in Q4 2023 was Griffin Asset Management, an estimated $186K added.
- The largest Accelerate Diagnostics seller in Q4 2023 was Alyeska Investment Group, an estimated $712K sold.
Based on aggregated 13F filings for Q4 2023.